Bristol Myers Squibb (BMY) — The Transparent Read
73/100Bullish$58.56 · uptrend
The weight of evidence leans bullish. Trend, momentum, and the macro base rate all align, and the only meaningful drag in the signal breakdown is proximity to resistance — a hurdle, not a reversal. My lean is that BMY breaks through $58.58 and the 71% historical edge plays out toward that +6.1% median. But I'd respect the level: a clean, sustained close above resistance is the confirmation that turns a coiled setup into a breakout. Until then, expect some friction.
BMY key levels
Show Your Work — every point in BMY's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Above 200-day MA Price is above its 200-day average — long-term trend is up. | technical | +8 |
| Above 50-day MA Trading above the 50-day average — medium-term momentum is positive. | technical | +5 |
| Golden cross 50-day average is above the 200-day (golden cross). | technical | +4 |
| RSI neutral RSI is 59 — neither overbought nor oversold. | technical | +0.94 |
| MACD positive MACD is above its signal line — momentum is building. | technical | +5 |
| Near resistance Pressing against resistance around $58.58. | technical | -4 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 71% of the time (median +6.1%). Historically favorable. | macro | +4.21 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, BMY was higher 90 days later 71% of the time (median move 6.0%). Confidence: high.
The read
BMY Knocks on the Door: Bullish Setup Coiled Right at Resistance
Bull case. This is a textbook uptrend. BMY trades above both its 50-day ($57.08) and 200-day ($53.21) moving averages, with a golden cross confirming the longer-term turn. MACD histogram sits positive at +0.30 — momentum is building — while RSI at 59 leaves room to run before overbought territory. The composite score of 73.2/100 lands firmly bullish. Crucially, the macro tailwind is real: in 38 analogous 'Rising inflation + Steady Fed' periods, BMY was higher 90 days later 71% of the time with a median gain of +6.1%, and that's a high-confidence read.
Bear case. The catch is location. At $58.56, price is pressing directly against resistance at $58.58 — the stock is at the ceiling, not in open air. That's a spot where rallies stall and rejections happen. RSI at 59 is constructive but not screaming strength, and a failure to break out could send price back toward the 50-day at $57.08 or even the $53.44 support. Buying right into resistance is buying at the most contested level on the chart.
What would change my mind. A decisive break and close below the 50-day MA at $57.08 — especially if MACD rolls negative — would invalidate the breakout thesis and put the $53.44 support in play. Conversely, a confirmed close above $58.58 would clear the runway.
BMY — frequently asked
Is BMY a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 73/100 read for Bristol Myers Squibb (BMY), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is BMY's Tallyread score calculated?
The 73/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect BMY?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), BMY was higher 90 days later 71% of the time, with a median move of 6.0%. Confidence: high.
Want a fresh read on BMY with the live chart and macro tape?
Run a live BMY read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell BMY. Markets are uncertain; do your own research.